Top

Gepubliceerd in:

01-08-2017 | Discussie

Denk tijdig aan metformine bij diabetes

Auteur: Nellie Jans

Gepubliceerd in: Huisarts en wetenschap | Uitgave 8/2017

Samenvatting

Diabetes mellitus type 2, ook wel kortweg DM2 genoemd, is een progressieve aandoening doordat de hyperglykemie en de verhoogde concentraties vrije vetzuren en triglyceriden de bestaande insulineresistentie en bètaceldisfunctie verder verergeren – een proces dat men ‘glucolipotoxiciteit’ noemt.

vorige artikel Counseling is dagelijks werk voor de huisarts

volgende artikel Sepsis herkennen bij een volwassene

Incidenties en prevalenties: diabetes 2015 [internet]. Utrecht: Nivel, 2016. https://www.nivel.nl/nl/NZR/incidenties-en-prevalenties, geraadpleegd mei 2017.

Ligthart S, Van Herpt TT, Leening MJ, Kavousi M, Hofman A, Stricker BH, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 2016;4:44–51.CrossRefPubMed

Rutten GEHM, De Grauw WJC, Nijpels G, Houweling ST, Van de Laar FA, Bilo HJ, et al. NHG-Standaard Diabetes mellitus type 2 (derde herziening). Huisarts Wet 2013;56:512–25.

Houweling ST, Kleefstra N, Holleman F, Verhoeven S, Bilo HJG. Protocollaire diabeteszorg. Zwolle: Stichting Langerhans, 2013. p. 4–1.

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE-guideline 28. London: NICE; 2015.

Inzucchi SE, Bergenstal RM, Buse JB, Silvio E, Michaela Diamant M, Ferrannini E, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–96.CrossRefPubMed

Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine. 2013;43:504–13.CrossRefPubMed

DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 2011;96:2354–66.CrossRefPubMed

Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–22.PubMed

10.

Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, et al. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 2012;19:755–64.CrossRefPubMed

11.

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.CrossRefPubMed

12.

Herman WH, Ye W, Griffin SJ, Simmons RK, Davies MJ, Khunti K, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 2015;38:1449–55.PubMed

13.

Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): A cluster-randomised trial. Lancet 2011;378:156–67.CrossRefPubMed

14.

Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.CrossRefPubMed

15.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.PubMed

16.

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008:358:2545–59PubMed

17.

Chen L, Pei J-H, Kuang J, Chen HM, Chen Z, Li ZW, et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2015;64(2):338–47.CrossRefPubMed

18.

Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:543–51.CrossRefPubMed

19.

Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 2015;75:1071–94.CrossRefPubMed

20.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313–24.CrossRefPubMed

21.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.PubMed

22.

Stevens JW, Khunti K, Harvey R, Johnson M, Preston L, Woods HB, et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Res Clin Pract 2015;107:320–31.CrossRefPubMed

23.

Stefan N, Staiger H, Wagner R, Machann J, Schick F, Häring HU, et al. A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia 2015;58:2877–84.CrossRefPubMed

24.

Griffin SJ. Initiation of cardioprotective medecin [mondelinge presentatie]. European Association for the Study of Diabetes (EASD) 2016 Annual Meeting, München, 2016.

Titel: Denk tijdig aan metformine bij diabetes
Auteur: Nellie Jans
Publicatiedatum: 01-08-2017
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Huisarts en wetenschap / Uitgave 8/2017
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI: https://doi.org/10.1007/s12445-017-0242-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2017

Anamnese van de huisarts

Sepsis herkennen bij een volwassene

Serieuze kritiek op de ggz

‘Investeer in het begin bij SOLK’

Iedere patiënt een eigen gebruiksaanwijzing

Herkennen van inflammatoir mammacarcinoom